{
  "id": 7557874,
  "title": "Mirum Pharmaceuticals at H.C. Wainwright conference: growth, catalysts",
  "url": "https://urgent.news/2026/09/15/mirum-pharmaceuticals-at-h-c-wainwright-conference-growth-catalysts",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-15T13:33:15.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/mirum-pharmaceuticals-at-hc-wainwright-conference-growth-catalysts-93CH-4901937"
  },
  "original_language": "en",
  "account": "On September 15, 2026, Mirum Pharmaceuticals (MIRM) highlighted its rapid growth at the H.C. Wainwright 28th Annual Global Investment Conference. The company emphasized strong sales, a promising revenue outlook, and upcoming clinical and regulatory milestones. MIRM's CEO, Chris Peetz, focused on the company's mission to develop treatments for rare diseases, particularly rare liver disorders. The company reported $176.2 million in revenue for Q2 2024, driven by LIVMARLI, which generated $129 million in sales, up 13% from the previous quarter. Mirum raised its full-year 2024 revenue guidance to $680 million to $700 million. The company expects 2024 to be a breakeven or slightly negative cash flow year, with positive cash flow expected in 2025. Peetz outlined MIRM's pipeline, including hepatitis delta, primary biliary cholangitis, primary sclerosing cholangitis, and fibrodysplasia ossificans progressiva. The company aims to build a commercial platform from its existing infrastructure. Peetz noted that adult PFIC has about 2,000 underdiagnosed patients in the U.S. as a significant growth opportunity. Several pipeline events are planned within the next year, including a September 26, 2024, PDUFA date for zilurgisertib and Phase III updates for brelovitug. Mirum's commercial business continued to perform strongly in Q2 2024, with combined revenue from approved medicines reaching $176.2 million. LIVMARLI's growth is driven by increased patient starts in Alagille syndrome, new pediatric dose adjustments, adult PFIC new patient starts, and international expansion in existing markets. Mirum aims to expand its commercial team to cover a broader prescriber base by the end of 2024 or early 2025.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Eupraxia Pharmaceuticals at H.C. Wainwright conference: focus on durability",
        "url": "https://urgent.news/2026/09/14/eupraxia-pharmaceuticals-at-h-c-wainwright-conference-focus-on",
        "published": "2026-09-14T18:56:56.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}